Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul;81(11):1349-1353.
doi: 10.1007/s40265-021-01561-7.

Amivantamab: First Approval

Yahiya Y Syed  1
Affiliations
Review

Amivantamab: First Approval

Yahiya Y Syed. Drugs. 2021 Jul.

Abstract

Amivantamab (amivantamab-vmjw; Rybrevant™), a bispecific monoclonal antibody targeting epidermal growth factor receptor (EGFR) and mesenchymal epithelial transition factor (MET), is being developed by Janssen Biotech for the treatment of non-small cell lung cancer (NSCLC). On 21 May 2021, amivantamab received its first approval in the USA for the treatment of adult patients with locally advanced or metastatic NSCLC harbouring EGFR Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy. Amivantamab is in preregistration for NSCLC in the EU, Australia, Japan, Canada, Switzerland and China. This article summarizes the milestones in the development of amivantamab leading to this first approval for NSCLC.

PubMed Disclaimer

References

    1. Neijssen J, Cardoso RMF, Chevalier KM, et al. Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. J Biol Chem. 2021. https://doi.org/10.1016/j.jbc.2021.100641 . - DOI - PubMed - PMC
    1. Moores SL, Chiu ML, Bushey BS, et al. A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors. Cancer Res. 2016;76(13):3942–53. - DOI
    1. Grugan KD, Dorn K, Jarantow SW, et al. Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells. MAbs. 2017;9(1):114–26. - DOI
    1. Janssen Biotech Inc. RYBREVANT (amivantamab-vmjw) injection, for intravenous use: US prescribing information. 2021. https://www.accessdata.fda.gov/ . Accessed 11 Jun 2021.
    1. US Food & Drug Administration. FDA approves first targeted therapy for subset of non-small cell lung cancer [media release]. https://www.fda.gov/ . 21 May 2021.

MeSH terms

LinkOut - more resources